CL2014000992A1 - Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer. - Google Patents

Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer.

Info

Publication number
CL2014000992A1
CL2014000992A1 CL2014000992A CL2014000992A CL2014000992A1 CL 2014000992 A1 CL2014000992 A1 CL 2014000992A1 CL 2014000992 A CL2014000992 A CL 2014000992A CL 2014000992 A CL2014000992 A CL 2014000992A CL 2014000992 A1 CL2014000992 A1 CL 2014000992A1
Authority
CL
Chile
Prior art keywords
preparation
pioglitazone
alzheimer
onset
progression
Prior art date
Application number
CL2014000992A
Other languages
English (en)
Spanish (es)
Inventor
Yumiko Ishii
Yutaka Tanque
Yusuke Murakawa
Kaoru Takenaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000992(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2014000992A1 publication Critical patent/CL2014000992A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014000992A 2011-10-21 2014-04-17 Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer. CL2014000992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21

Publications (1)

Publication Number Publication Date
CL2014000992A1 true CL2014000992A1 (es) 2014-09-05

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000992A CL2014000992A1 (es) 2011-10-21 2014-04-17 Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer.

Country Status (30)

Country Link
US (1) US9907789B2 (enExample)
EP (1) EP2768487B1 (enExample)
JP (1) JP6093762B2 (enExample)
KR (1) KR20140081826A (enExample)
CN (1) CN104039313A (enExample)
AP (1) AP2014007645A0 (enExample)
AR (1) AR088398A1 (enExample)
AU (1) AU2012326976B2 (enExample)
BR (1) BR112014008744A2 (enExample)
CA (1) CA2852417A1 (enExample)
CL (1) CL2014000992A1 (enExample)
CO (1) CO6960544A2 (enExample)
CR (1) CR20140213A (enExample)
DO (1) DOP2014000077A (enExample)
EA (1) EA201490840A1 (enExample)
EC (1) ECSP14013328A (enExample)
IL (1) IL232114A0 (enExample)
IN (1) IN2014DN03169A (enExample)
MA (1) MA35717B1 (enExample)
MX (1) MX2014004679A (enExample)
NZ (1) NZ624275A (enExample)
PE (1) PE20141189A1 (enExample)
PH (1) PH12014500856A1 (enExample)
SG (2) SG2014012025A (enExample)
TN (1) TN2014000152A1 (enExample)
TW (1) TW201323018A (enExample)
UA (1) UA113858C2 (enExample)
UY (1) UY34403A (enExample)
WO (1) WO2013058409A1 (enExample)
ZA (1) ZA201403103B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
ES2668422T3 (es) 2012-04-20 2018-05-18 Gilead Sciences, Inc. Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE69332081T2 (de) 1992-09-18 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelzubereitung mit verzögerter freisetzung
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2003013609A1 (fr) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
IN192749B (enExample) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
EP1607088B1 (en) 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
WO2004108161A1 (ja) 2003-06-06 2004-12-16 Takeda Pharmaceutical Company Limited 固形製剤
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
EP1789022A2 (en) 2004-08-31 2007-05-30 Pfizer Products Incorporated Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
KR20080058413A (ko) 2005-09-22 2008-06-25 에스비 팜코 푸에르토 리코 인크. Ａｐｏｅ4 음성 환자에서의 인지 기능의 개선을 위한ｐｐａｒ-감마 작동제
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
KR20080080126A (ko) 2005-12-22 2008-09-02 다케다 야쿠힌 고교 가부시키가이샤 인슐린 감작제를 함유하는 고체 제제
PL2002828T3 (pl) 2006-03-30 2019-11-29 Nippon Zoki Pharmaceutical Co Stały preparat farmaceutyczny
PE20080696A1 (es) 2006-04-27 2008-08-04 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol y clorhidrato de pioglitazona
AU2008213744B2 (en) 2007-02-09 2013-12-05 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
AU2009298684B2 (en) 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
PH12013501450A1 (en) 2011-01-10 2013-08-28 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer`s diseases
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
EP2768487B1 (en) 2020-06-03
US9907789B2 (en) 2018-03-06
TN2014000152A1 (en) 2015-09-30
ZA201403103B (en) 2015-08-26
IL232114A0 (en) 2014-06-30
EP2768487A1 (en) 2014-08-27
AU2012326976B2 (en) 2017-08-17
AP2014007645A0 (en) 2014-05-31
KR20140081826A (ko) 2014-07-01
BR112014008744A2 (pt) 2017-04-18
AU2012326976A1 (en) 2014-05-29
NZ624275A (en) 2016-09-30
AU2012326976A2 (en) 2014-06-12
AR088398A1 (es) 2014-05-28
PH12014500856A1 (en) 2014-05-19
DOP2014000077A (es) 2014-07-15
JP6093762B2 (ja) 2017-03-08
JP2014530802A (ja) 2014-11-20
PE20141189A1 (es) 2014-09-24
SG2014012025A (en) 2014-06-27
CR20140213A (es) 2014-06-18
UA113858C2 (uk) 2017-03-27
ECSP14013328A (es) 2014-05-31
WO2013058409A1 (en) 2013-04-25
SG10201700121YA (en) 2017-03-30
MA35717B1 (fr) 2014-12-01
UY34403A (es) 2013-05-31
CA2852417A1 (en) 2013-04-25
CO6960544A2 (es) 2014-05-30
EA201490840A1 (ru) 2014-08-29
MX2014004679A (es) 2014-08-01
CN104039313A (zh) 2014-09-10
US20140248362A1 (en) 2014-09-04
IN2014DN03169A (enExample) 2015-05-22
TW201323018A (zh) 2013-06-16

Similar Documents

Publication Publication Date Title
HRP20200197T1 (hr) 5-((halofenil)-3-halo-piridin-2-il)-nitrilni derivati kao posrednici u pripremi [(5-(halofenila)-3-hidroksipiridin-2-karbonil)-amino]derivata alkanske kiseline
CL2014000992A1 (es) Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
EP2773637A4 (en) BENZOLSULFONAMIDE COMPOUNDS AND THEIR USE AS MEDICAMENTS
BR112013018953A2 (pt) composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais.
IL228925A0 (en) Benzothiazole compounds and their pharmaceutical use
IL226049A0 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
IL228845A0 (en) Antimicrobial compounds and methods of making and using the same
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
CL2013003094A1 (es) Composiciones activas de antitranspirante que comprende una sal de aluminio y una especie de cation polihidroxioxoaluminio; metodo de fabricacion de la misma; y su uso.
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
IL228666A0 (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
EP2753310A4 (de) Formulierung zur kontrollierten freisetzung eines oder mehreren stoffe im verdauungstrakt eines säugetiers
EP2747779A4 (en) HERPES SIMPLEX VIRUS VACCINE NANOEMULSION
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.